346 related articles for article (PubMed ID: 27270655)
1. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
4. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
Xu Y; Zhang Y; Wang X; Kang J; Liu X
BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
[TBL] [Abstract][Full Text] [Related]
9. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C
Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
12. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
14. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
[TBL] [Abstract][Full Text] [Related]
15. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
Sun J; Ning H; Sun J; Qu X
Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
[TBL] [Abstract][Full Text] [Related]
16. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis.
Zhan H; Ma JY; Jian QC
Clin Chim Acta; 2018 Sep; 484():136-140. PubMed ID: 29856976
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M; Buti S; Conti A; Porta C; Procopio G; Sternberg CN; Bracarda S; Basso U; De Giorgi U; Rizzo M; Derosa L; Ortega C; Massari F; Milella M; Bersanelli M; Cerbone L; Muzzonigro G; Burattini L; Montironi R; Santini D; Cascinu S
Target Oncol; 2015 Dec; 10(4):517-22. PubMed ID: 25559290
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
Lu Y; Jiang J; Ren C
PLoS One; 2020; 15(4):e0230979. PubMed ID: 32241019
[TBL] [Abstract][Full Text] [Related]
20. Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Clin Genitourin Cancer; 2017 Aug; 15(4):495-501. PubMed ID: 28363437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]